EGFR and non-small cell lung carcinoma: The EGFR mutations, first reported in 2004 [95], usually contain in-frame duplications/insertions in exon 20, in-frame deletions (around amino acid residues 747 to 750) in exon 19 and single missense mutations in exon 21_(L858R mutation) [96], and reveal a potential responsiveness of NSCLC to the tyrosine kinase inhibitors [97].